Norgine receives positive CHMP opinion recommending approval of NPJ5008 (dantrolene sodium hemiheptahydrate) for the treatment of malignant hyperthermia

Amsterdam (ots/PRNewswire) - Norgine B.V. today announced that the Committee for
Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
has adopted a positive opinion recommending approval of NPJ5008 (dantrolene
sodium hemiheptahydrate) for the treatment of malignant hyperthermia.

The European Commission (EC) will now review the CHMP's recommendation. If
approved, the centralized marketing authorization would be valid in all 27 EU
member states, as well as in Iceland, Liechtenstein, and Norway and would be the
first new treatment in Europe for malignant hyperthermia in over forty years.
Submissions to the UK MHRA and Swiss Medic are ongoing.

Dr David Gillen , Chief Medical Officer of Norgine, added: "We are delighted to
have received a positive CHMP opinion for NPJ5008. Malignant hyperthermia (MH)
is thankfully a rare medical emergency following anaesthesia. Nevertheless, it
is clear that effective management of MH is critically important to improve
clinical outcomes. NPJ5008 will allow faster administration compared to the
existing dantrolene formulation and therefore, we believe, better outcomes for
all European patients with MH."

For further information please contact:

mailto:[e-mail]

http://www.norgine.com/

Follow us @norgine

Notes to Editors:

About Malignant Hyperthermia

Malignant hyperthermia (MH) is a rare life-threatening pharmacogenetic disorder
of skeletal muscles that presents as an exaggerated hypermetabolic response to
volatile anaesthetic agents and depolarizing muscle relaxants.[1]

About NPJ5008

NPJ5008 is a novel formulation of dantrolene that has been developed by Norgine
to shorten preparation and administration times versus DANTRIUM IV (dantrolene
sodium). Each vial of NPJ5008 contains 120mg of dantrolene and is reconstituted
in 20 mL of water for injections for intravenous administration.[2]

About Norgine

Norgine is a leading European specialist pharmaceutical company that has been
bringing transformative medicines to patients for over a century. Our commitment
to transforming people's lives drives everything we do and our European
experience, fully integrated infrastructure and exceptional partnership approach
enable us to quickly apply creative solutions to bring life-changing medicines
to patients that they may not otherwise be able to access. Norgine is proud to
have helped more than 25 million patients around the world in 2022 and generated
EUR530 million in net product sales, a growth of nearly 5% over 2021.

Norgine has a direct presence in 16 European countries, as well as Australia and
New Zealand. We also have a strong global network of partnerships in non-Norgine
markets. We are a flexible and fully integrated pharmaceutical business, with
manufacturing (Hengoed, Wales and Dreux, France), third party supply networks
and significant product development capabilities, in addition to our sales and
marketing infrastructure. This enables us to acquire, develop and commercialise
specialist and innovative products that make a real difference to the lives of
patients around the world.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

References:

1. Kaur et al. Mo Med. 2019;116(2):154-159.
2. Ng Kwet Shing RH, et al. Eur J Anaesthesiol. 2024;41:1-10.

Logo: https://mma.prnewswire.com/media/597589/Norgine_Logo.jpg

View original content: https://www.prnewswire.co.uk/news-releases/norgine-receiv
es-positive-chmp-opinion-recommending-approval-of-npj5008-dantrolene-sodium-hemi
heptahydrate-for-the-treatment-of-malignant-hyperthermia-302099840.html

Contact:

Richard Hinde,
[phone]

Additional content: http://presseportal.de/pm/174010/5744391
OTS: Norgine BV